activators and stimulators of the sGC have been suggested as new therapeutic tools for the treatment of lung vascular disorders that might have even higher potency than PDE inhibitors or exogenously applied NO.
Adaptation of Blood Flow to Ventilation in the Pulmonary Circulation
Adaptation of perfusion to ventilation is one of the most important features of pulmonary physiology. The key regulator of this phenomenon is hypoxic vasoconstriction, a reflex originally described by von Euler and Liljestrand (Von Euler and Liljestrand. 1946) , which ensures optimized gas exchange (Grimminger et al. 1995; Weissmann et al. 2001) . As changes in the distribution of blood flow to different areas of the lung must occur rapidly (e.g., when changing from prone to supine position, or when stressing the pulmonary circulation upon exercise), adjustments of vessel diameter in the respective regions of the lung must be regulated immediately (Cohen et al. 1996; Hillier et al. 1997) . A key molecule for this fast response, which links alveolar ventilation (and thus the degree of regional oxygenation) to local lung perfusion, is nitric oxide (NO): it has been conclusively shown that the fall in lung NO production precedes the rise in pulmonary pressure upon induction of acute experimental hypoxic pulmonary vasoconstriction (HPV), as well as that lung NO production is closely related to the degree of alveolar ventilation .
2 Proof of Principle: NO-Inhalation to Improve Gas Exchange in Acute Lung Failure
The adult respiratory distress syndrome (ARDS) is characterized by gas exchange disturbances as a result of (1) loss of alveolar-capillary barrier integrity, with reduced diffusion capacity, (2) increases in ventilation/perfusion mismatch, and (3) acute pulmonary hypertension (Radermacher et al. 1989; Melot et al. 1989 ). Several attempts have been undertaken to improve gas exchange with systemically applied vasodilators, which resulted in reduction of pulmonary hypertension, but were hampered by concomitant worsening in gas exchange (Rossaint et al. 1993) . Inhaled nitric oxide administered in patients with ARDS could for the first time display features of a vasodilator that selectively dilates vessels in the lung (pulmonary selectivity), and in addition preferentially dilates vessels in well ventilated areas only (intrapulmonary selectivity) ( Fig. 1 ) . Improvements in oxygenation in this patient collective were attributed to a reduction in intrapulmonary shunt-perfusion. In contrast, infused prostacyclin -although potently reducing pulmonary pressure -had no selectivity for the pulmonary circulation (i.e., equipotently reduced systemic vascular resistance) and in addition resulted in deteriorated Rationale for intrapulmonary selective vasodilatation by sildenafil. Nitric oxide (NO) is released in the lung, preferentially in well ventilated areas of the lung (V) and thus directs blood flow (Q) into these regions by local vasodilatation. In contrast, in regions with less ventilation, only little NO is produced and resistance vessels in these regions constrict due to hypoxic pulmonary vasoconstriction reflex (a). In areas with high local NO production, more cGMP is released as a second messenger of NO-response and concomitantly PDE5 activity is upregulated. Again only little PDE5 activity is present in areas of less ventilation (b). The PDE5 inhibitor sildenafil, despite systemic administration, preferentially acts in areas of good regional ventilation, thereby augmenting the endogenous vasodilatory action of NO redirecting blood flow optimizing ventilation/perfusion matching (c) oxygenation by worsening of ventilation/perfusion matching. However, only few reports support the long term treatment of chronic pulmonary hypertension by continuous therapy with NO inhalation (Channick et al. 1996; Higenbottam et al. 2000) .
PDE5 in the Pulmonary Circulation: Gateway Opener for Oral Therapy
In patients with idiopathic pulmonary arterial hypertension (iPAH), intravenous prostacyclin has been demonstrated to be a potent pulmonary vasodilator, and long-term infusion of this prostanoid was found to improve exercise tolerance and survival in these patients (Egan 1999) . However, in the presence of ventilatory disorders, systemic administration of vasodilators regularly increases the blood flow to low or nonventilated lung areas by interfering with the physiological hypoxic vasoconstrictor mechanism, thereby worsening preexistent ventilation(V)/perfusion(Q) mismatch and shunt flow (Agusti and Rodriguez-Roisin 1993; Olschewski et al. 1999) . Decrease in arterial oxygenation and wasting of the small ventilatory reserve of these patients are the disadvantages of this effect. Inhalation of a vasorelaxant agent to achieve selective pulmonary vasodilation and to redistribute blood flow to the well-ventilated lung areas is an appealing concept to circumvent these hazards (Walmrath et al. 1993; Olschewski et al. 1996) . In pulmonary arterial hypertension, daily repetitive aerosolization of the long-acting prostacyclin analogue iloprost has been suggested as a new therapeutic concept (Olschewski et al. 1996 (Olschewski et al. , 1998 (Olschewski et al. , 2000 (Olschewski et al. , 2002 Hoeper et al. 2000) . In secondary pulmonary hypertension linked to lung fibrosis, inhaled iloprost was found to decrease the pulmonary vascular resistance similar to intravenous prostacyclin, but not to increase shunt flow as occurred during prostanoid infusion in these patients (Rubin 1997) . Continuous inhalation strategies are, however, hampered by practical burdens due to the cumbersome use of inhalation devices as well as the necessity of frequent inhalations over the daytime.
Phosphodiesterases are a superfamily of enzymes that inactivate cyclic adenosine monophosphate and cyclic guanosine monophosphate, the second messengers of prostacyclin and nitric oxide. The phosphodiesterases have different tissue distributions and substrate affinities (Fig. 2) ; in particular, phosphodiesterase-5 is abundantly expressed in lung tissue (Beavo 1995 (preferential lung over systemic vasodilation) and "supra-selective" (vasodilation in well-ventilated, but not in nonventilated lung areas) pulmonary vasorelaxation was the phosphodiesterase (PDE) type 5 inhibitor sildenafil: In patients with lung fibrosis and concomitant pulmonary hypertension, known to be susceptible to gas exchange abnormalities due to underlying intrapulmonary shunt flow, the pharmacological properties of sildenafil were tested (Ghofrani et al. 2002b) . Oral sildenafil was found to cause pulmonary vasodilation in patients with lung fibrosis and pulmonary hypertension, with an overall potency corresponding to that of intravenous prostacyclin (Fig. 3 ). Most notably, in contrast to the infused prostanoid, selectivity for well-ventilated lung areas was demonstrated for sildenafil, resulting in an improvement rather than a deterioration of gas exchange (Fig. 4) . Controlled randomized trials, however, are needed to confirm the therapeutic benefit in this secondary form of pulmonary vascular disorder. However, this unique profile, never before disclosed for a systemically administered agent, suggested that the PDE-5 inhibitor sildenafil might be a promising candidate for long-term treatment of severe forms of pulmonary hypertension.
Clinical Experience with Sildenafil for the Treatment of Chronic Pulmonary Hypertension
A case report of a patient suffering from severe pulmonary arterial hypertension who was treated chronically with very high doses of oral sildenafil indicated that this approach might be effective (Prasad et al. 2000) . In pediatric patients, the administration of intravenous prostacyclin is even more hampered by problems associated with i.v. mode of administration than in adults. A study reporting the successful use of oral sildenafil in a child with severe pulmonary hypertension attracted attention, not only within the medical community, but also in the media (Abrams et al. 2000; Patole and Travadi 2002; Oliver and Webb 2002) . Trials addressing the characterization of the acute effects of sildenafil on pulmonary and systemic hemodynamics in a larger number of patients with pulmonary arterial hypertension showed that sildenafil effectively reduced pulmonary vascular resistance in a dose-dependent manner (Ghofrani et al. 2002a ). In combination with a prostanoid (inhaled iloprost), augmentation of the pulmonary vasodilatory effect of each single agent was observed (Ghofrani et al. 2002a; Wilkens et al. 2001 ). Long-term treatment of patients with pulmonary arterial hypertension was investigated in a number of single-centre studies, all confirming the efficacy and tolerance of chronic oral sildenafil treatment (Kothari and Duggal 2002; Sastry et al. 2002 Sastry et al. , 2004 . In patients with deteriorating severe PAH despite ongoing prostanoid treatment, additional long-term administration of oral sildenafil improved exercise capacity and pulmonary hemodynamics (Ghofrani et al. 2003a ). Thus, the combination of prostanoids and sildenafil has potential as a possible future treatment for pulmonary hypertension. Numerous reports on the clinical use of sildenafil in pulmonary arterial hypertension in uncontrolled trials have been published to date Fig. 4 Pulmonary shunt flow at baseline and in response to vasodilator challenge (assessed by MIGET). The percentage (mean ± SD) of shunt perfusion of total pulmonary blood flow is displayed at baseline (Base), during NO inhalation (NO (inh.)), during infusion of prostacyclin (PGI (i.v.)), and after oral sildenafil (Sil (oral)). (Kothari and Duggal 2002; Sastry et al. 2002; Watanabe et al. 2002; Zimmermann et al. 2002; Singh et al. 2002; Lepore et al. 2002; Michelakis et al. 2002; Zhao et al. 2003 ). Sildenafil appears to be effective for treating patients with pulmonary hypertension of diverse causes in addition to idiopathic pulmonary arterial hypertension. In patients suffering from human immunodeficiency virus (HIV)-related pulmonary hypertension, sildenafil was effective in reducing the pulmonary vascular resistance, as it was in iPAH (Schumacher et al. 2001; Carlsen et al. 2002) . Recent data suggest that long-term oral sildenafil treatment in patients with nonoperable chronic thromboembolic pulmonary hypertension or portopulmonary hypertension can be beneficial (Ghofrani et al. 2003b; Reichenberger et al. 2007 ). The importance of this finding lies in the fact that there is little to offer as a therapeutic option for these patients, with the exception of lung transplantation. 
SUPER-1 Sildenafil improves exercise tolerance in PAH
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Week 12 Week 8 Fig. 5 Key results from the pivotal RCT with sildenafil in PAH (SUPER-1 trial). Changes in the six-minute walking distance as compared to baseline values after 4, 8, and 12 weeks, respectively, are shown in this graph. Patients received either placebo or 20, 40, or 80 mg sildenafil TID with a placebo or sildenafil (20, 40, or 80 mg) orally, three times daily, for 12 weeks (Fig. 5) . The primary end-point of this trial -as in many similar trials with other medications -was a significant improvement comparing baseline to week 12 in the 6-min walk test. Sildenafil (in all the tested doses) improved exercise capacity (up to 50 m (placebo corrected value) in the 80 mg three times daily (TID) group), functional class, and hemodynamics, as compared to placebo-treated patients, and was very well tolerated (Galie et al. 2005) . Additionally, patients completing the doubleblind phase were able to enter a long-term extension trial, which was conducted over a 2-year period and received 80 mg sildenafil TID. The increase of the 6-min walk distance achieved after 3 months in the placebo-controlled phase was maintained even after 1 year of therapy, as were the improvements in functional class, both results were strongly indicative of the maintenance of the effect despite the severity of the disease. Based on the very favorable mid-and long-term effects of this new oral treatment, sildenafil was approved by the FDA and the EMEA in 2005 for the treatment of patients suffering from PAH. Both agencies decided to approve only the 20 mg TID dose, as only a flat (nonsignificant) dose-effect relationship between 20-80 mg TID was observed regarding the primary end-point of the study, the increase in 6-min walking distance over 12 weeks treatment. An analysis of sildenafil plasma levels in the SUPER-1 study showed no dose-effect relationship with the doses that were studied (data on file, unpublished). There is evidence from some clinical and experimental settings that the duration of action of sildenafil may not be accurately reflected by plasma-levels and the applied dosage (Moncada et al. 2004) . It has been shown that the affinity of sildenafil to PDE5 remains increased after intracellular phosphorylation of the enzyme (Mullershausen et al. 2003) . In addition, the conformational changes of PDE5 and the slow dissociation rate of sildenafil from the enzyme may contribute to the flat dose-effect relationship (Francis et al. 1998; Gopal et al. 2001; Corbin and Francis 2002; Huai et al. 2004) . Another possible explanation is the hypothesis that sildenafil binding to the catalytic site of PDE5 could occur at higher affinity and may thus retard clearance of the inhibitor from the cell. On the contrary, in the SUPER-1 trial there were clear trends in some secondary endpoints (some showed statistically significant differences between the three applied doses), indicating that, for a subgroup of patients, higher doses might be more efficacious than the approved 20 mg TID dosage. Moreover, in the majority of previous short-and long-term studies, daily doses of 100 up to 300 mg were investigated and reported to be efficacious and well tolerated (Ghofrani et al. 2002a; Wilkens et al. 2001; Kothari and Duggal 2002; Sastry et al. 2004; Michelakis et al. 2003) . Thus, future studies are warranted, addressing the long-term efficacy of 20 mg TID or even smaller doses of sildenafil for the treatment of PAH.
More PDE5 Inhibitors
In a comparative clinical trial, 60 consecutive PAH patients (NYHA classification II-IV) undergoing right heart catheterization for acute pulmonary vasoreactivity testing received initial short-term nitric oxide inhalation and were subsequently assigned to oral intake of 50 mg sildenafil (n = 19), 10 mg (n = 7) or 20 mg (n = 9) vardenafil, or 20 mg (n = 9), 40 mg (n = 8), or 60 mg (n = 8) tadalafil (Ghofrani et al. 2004) . Hemodynamics and gas exchange responses were assessed over a subsequent 120 min observation period. All three PDE-5 inhibitors caused significant pulmonary vasorelaxation, accompanied by an increase of cardiac output, with maximum effects obtained after 40-45 min (vardenafil), 60 min (sildenafil), and 75-90 min (tadalafil). Sildenafil and tadalafil, but not vardenafil, caused a significant reduction of the pulmonary to systemic vascular resistance ratio. Significant improvement in systemic arterial oxygenation, corresponding to that observed during NO inhalation, was noted only with sildenafil. Thus, the three PDE-5 inhibitors appeared to differ in their kinetics of pulmonary vasorelaxation (most rapid effect produced by vardenafil), selectivity for the pulmonary circulation (sildenafil and tadalafil, but not vardenafil), and impact on systemic arterial oxygenation (improvement only after sildenafil). A controlled clinical trial investigating the effects of the PDE5 inhibitor tadalafil in patients with PAH has recently come to an end (LVGY and LVGX); the results will be released in late 2008.
Soluble Guanylate Cyclase: A New Target for the Treatment of Pulmonary Vascular Disorders
The downstream effector of NO is the enzyme soluble guanylate cyclase (sGC), which synthesizes the second messenger cyclic guanosine monophosphate (cGMP). Soluble GC is typically found as a heterodimer, consisting of a larger α-subunit and a smaller haem-binding β-subunit. The binding of NO to sGC results in activation and synthesis of the second messenger cGMP. Further, cGMP activates cGMP-dependent protein kinases (PKGs), leading to a reduction of cytosolic Ca 2+ concentration and desensitization of the actin-myosin contractile system. Although impairment of the endothelium-dependent regulation of pulmonary vascular tone is consistently reported, the analysis of the role of sGC in chronic hypoxia-induced PAH has yielded conflicting data, with both increases and decreases of sGC protein expression described (Hassoun et al. 2004; Li et al. 2001; Li et al. 1999) . Therapeutic potential has been reported for YC-1, which acts as an "NO-sensitizer," greatly enhancing the sensitivity of sGC towards NO Friebe et al. 1996) . YC-1 increases cGMP in smooth muscle cells and induces a dosedependent vasodilation of endothelium-denuded rat aortic rings (Mulsch et al. 1997; Wegener and Nawrath 1997; Galle et al. 1999 ). Furthermore, YC-1 has been shown to inhibit the adhesion and aggregation of platelets (Teng et al. 1997; Wu et al. 1995; . Recently, the compound Bay 41-2272, which stimulates sGC directly and enhances the sensitivity of sGC to NO, was shown to be a systemic and pulmonary vasodilator Boerrigter et al. 2003 ). Furthermore, it augments the vasodilator response to inhaled NO when acute pulmonary hypertension is produced in lambs (Evgenov et al. 2004) . While Bay 41-2272 activates sGC in its native form, another compound, Bay 58-2667, has recently been shown to activate sGC even in its oxidized or heme-free form and independent of the activity of nitric oxide (Stasch et al. 2002) . In animal models of pulmonary hypertension, it was demonstrated that both the soluble guanylate cyclase stimulator Bay 41-2272 and the soluble guanylate cyclase activator Bay 58-2667 reverse pulmonary hypertension in chronically hypoxic mice and monocrotaline-injected rats. Notably, treatment with these agents was commenced only after full establishment of pulmonary hypertension and right heart hypertrophy, with structural changes in the lung's vasculature. The compound Bay 41-2272 is a novel NO-independent stimulator of sGC with similar characteristics to YC-1 (but with higher potency of about two to three orders of magnitude) and no PDE 5 inhibitory activity Stasch et al. 2002) . A deeper molecular understanding and encouraging pre-clinical results with stimulators and activators of sGC warranted further clinical development of compounds from this class for the treatment of pulmonary vascular disorders. In a first clinical trial of patients with moderate-to-severe PH (pulmonary arterial hypertension, distal chronic thromboembolic PH, or PH with mild to moderate interstitial lung disease), the safety, tolerability, and efficacy of the oral sGC stimulator BAY 63-2521 was evaluated. After the optimal tolerated dose was identified by initial patient studies, pharmacodynamic and pharmacokinetic parameters were assessed following a single dose administration (2.5 or 1 mg) in 19 patients. Fig. 6 Molecular pathology of pulmonary hypertension. The three major molecular pathways for pulmonary hypertension that are currently addressed by medical treatments are depicted in this picture. Prostacyclin is produced by prostacyclin synthase and activates the adenylate cyclase (AC), which produces the second messenger cAMP, leading to vasodilatation and antiproliferation. The NO pathway operates via activation of the sGC and elevation of cGMP, resulting in beneficial vasorelaxation and antiproliferation. Therapeutically this pathway can be addressed either by direct stimulation of the sGC, for example, with Bay 63-2521 or by administration of a PDE5 inhibitor. Lastly, the endothelin mediated effects of vasoconstriction and proliferation can be counteracted by the administration of endothelin receptor antagonists In this short term trial, BAY 63-2521 had a favorable safety profile at a single dose 2.5 mg. It significantly improved all major hemodynamic parameters in patients with PH in a dose-dependent manner, to a greater extent than inhaled NO, while maintaining mean systolic blood pressure above 110 mmHg. These results supported the view that sGC stimulators may have potential as a novel therapy for PH and warranted further investigation. Recently, clinical phase II and III trials in chronic pulmonary hypertension have been initiated with these compounds. Provided the outcome of these trials is positive, chemical sGC activators and stimulators may soon find their way into the list of molecular targets for the treatment of pulmonary vascular disorders (Fig. 6 ).
